Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
01/08/201706:00Business WireAcceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth DiseaseNASDAQ:XLRNAcceleron Pharma Inc
27/07/201706:00Business WireAcceleron to Webcast Second Quarter 2017 Financial Results on August 3, 2017NASDAQ:XLRNAcceleron Pharma Inc
19/07/201716:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
10/07/201713:17Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
07/07/201715:59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
23/06/201701:30Business WireAcceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the Europ...NASDAQ:XLRNAcceleron Pharma Inc
23/06/201701:30Business WireAcceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congre...NASDAQ:XLRNAcceleron Pharma Inc
12/06/201715:30Business WireAcceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell CarcinomaNASDAQ:XLRNAcceleron Pharma Inc
01/06/201706:30Business WireCelgene & Acceleron Complete Target Enrollment in the MEDALIST & BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic S...NASDAQ:XLRNAcceleron Pharma Inc
01/06/201706:00Business WireAcceleron to Participate in Two Healthcare Investor Conferences in JuneNASDAQ:XLRNAcceleron Pharma Inc
18/05/201706:00Business WireAcceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology AssociationNASDAQ:XLRNAcceleron Pharma Inc
08/05/201715:37Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
08/05/201707:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
08/05/201706:00Business WireAcceleron Pharma Reports First Quarter 2017 Operational and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
06/05/201706:00Business WireLuspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic SyndromesNASDAQ:XLRNAcceleron Pharma Inc
02/05/201715:30Business WireAcceleron Announces Management ChangeNASDAQ:XLRNAcceleron Pharma Inc
01/05/201708:13PR Newswire (US)Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of BiologicsNASDAQ:XLRNAcceleron Pharma Inc
01/05/201706:00Business WireAcceleron to Participate in Two Healthcare Investor Conferences in MayNASDAQ:XLRNAcceleron Pharma Inc
27/04/201706:35Business WireAcceleron Provides Clinical Development Updates on Luspatercept ProgramNASDAQ:XLRNAcceleron Pharma Inc
26/04/201706:00Business WireAcceleron to Host Webcast to Review First Quarter 2017 Financial and Operational Results on May 8, 2017NASDAQ:XLRNAcceleron Pharma Inc
13/04/201715:32Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
13/04/201715:30Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
06/04/201706:00Business WireAcceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic SyndromesNASDAQ:XLRNAcceleron Pharma Inc
22/03/201714:59Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
16/03/201706:00Business WireAcceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease & Host Educatio...NASDAQ:XLRNAcceleron Pharma Inc
08/03/201716:45Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:XLRNAcceleron Pharma Inc
01/03/201707:12Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XLRNAcceleron Pharma Inc
01/03/201706:00Business WireAcceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
28/02/201706:00Business WireAcceleron to Participate in Two Healthcare Investor Conferences in MarchNASDAQ:XLRNAcceleron Pharma Inc
22/02/201706:00Business WireAcceleron Pharma to Webcast Conference Call of Fourth Quarter and Year Ended 2016 Financial Results on March 1, 2017NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN